Project description:Results: Normal tissue contamination caused misclassification of tumors in all predictors, but different breast cancer predictors showed different susceptibility to normal tissue bias. Sensitivity and negative predictive value (NPV) of the PAM50 assay was improved by accounting for normal tissue. Conclusions: Normal tissue sampled concurrently with tumor tissue is an important source of bias in genomic predictors. Adjustments for normal tissue contamination could improve the application of breast cancer genomic predictors in both research and in clinical settings. Reference x breast tumor samples.
Project description:Results: Normal tissue contamination caused misclassification of tumors in all predictors, but different breast cancer predictors showed different susceptibility to normal tissue bias. Sensitivity and negative predictive value (NPV) of the PAM50 assay was improved by accounting for normal tissue. Conclusions: Normal tissue sampled concurrently with tumor tissue is an important source of bias in genomic predictors. Adjustments for normal tissue contamination could improve the application of breast cancer genomic predictors in both research and in clinical settings.
Project description:Future improvements in the field of breast cancer prevention, diagnosis and treatment require deeper knowledge and better understanding of the molecular processes and signaling pathways that lead to the transformation of normal cells to cancer ones and the disease progression. Quantitative proteome profiling of fresh frozen breast tissue and tumor samples may accelerate and facilitate this process. Liquid chromatography (LC) hyphenated to tandem mass spectrometry (MS/MS) technique in data-independent SWATH acquisition mode is a powerful tool for such profiling, because all the precursor ions are fragmented there, which enables label-free identification and quantification of theoretically all proteins in the sample. In this study we performed microLC separation before SWATH-MS analysis. The spectral library, which is necessary for SWATH quantification of the investigated samples, consisted of proteins identified by protein database search of the MS/MS spectra obtained by the information-dependent acquisition (IDA) screening of both normal human breast tissue and breast tumor samples, which were additionally enriched in low abundant proteins by immunoaffinity depletion from 14 high abundant serum proteins. Using the described methodology we detected 547 proteins in all qualitative experiments, which served then as a spectral library for further label-free SWATH quantification of separate breast tumor and corresponding normal breast tissue samples of 8 patients. Among them, 299 proteins were successfully quantified. Levels of 188 of them varied significantly (p<0.05) between normal breast tissue and breast tumor samples. 31proteins were up-regulated and 14 were down-regulated at least two fold in breast tumors comparing to normal breast tissues.
Project description:Genome wide DNA methylation profiling of normal and tumoral tissues of the breast. The Illumina Infinium 450k Human DNA methylation Beadchip was used to obtain DNA methylation profiles across approximately 450 thousand CpGs in fresh frozen tissue samples (40 primary breast tumours and 17 normal breast tissues). Samples included morphologically normal samples of each tissue and tumor samples.
Project description:Genome wide DNA methylation profiling of irradiated and non-irradiated breast tumor samples and normal control tissue. The Illumina Infinium 27k Human DNA methylation Beadchip, Genome Build 36 was used to obtain DNA methylation profiles across approximately 27,000 CpGs in breast tumor samples. Samples included 20 non-irradiated tumor samples, 19 irradiated tumor samples and 9 normal controls.
Project description:Breast cancer and normal breast tissue samples to estimate the effect of contamination of breast cancer samples with normal breast tissue
Project description:We performed high throughput transcriptome of breast cancer and normal tissues, identifying lincRNA associated molecular subtype with powerful capacity to distinct breast cancer population and predict prognosis. We also identified subtype-specific lincRNAs that may be a useful complement to intrinsic molecular subtype classification when divergence emerges among pathologists.Paired-end transcriptome sequencing were carried out on a cohort of 33 breast tissues from 11 groups including five breast cancer subtypes including luminal A (LA), luminal B (HER2 negative)(LB, HER2-), luminal B (HER2 positive) (LB, HER2+), HER2 and tripple negative breast cancer (TNB), adjacent noncancerous breast tissue (ANT, three samples for each subtype) and the complete normal breast tissues (three samples)
Project description:To develop a classifier based on microRNAs for primary tumor site identification of liver core biopsies and to explore the influence of surrounding normal liver tissue on classification. Tissue samples from 333 patients, corresponding to one of the following ten assay classes, were obtained from archives of the pathology department, Copenhagen University Hospital, Rigshospitalet, Denmark: Lung cancer, breast cancer, gastric/cardia cancer, colorectal cancer, bladder cancer, pancreatic cancer, hepatocellular carcinoma, cholangiocarcinoma, squamous cell cancers of different origin, and normal liver tissue
Project description:Comparision of CA1a cells grown in normal breast tissue pressure (NBP, 140 Pa) and breast tumor tissue pressure (BTP, 5000 Pa). Both conditions cultured in triplicates and quantified using TMT 6plex.
TMT 126-128 - NBP
TMT 129-131 - BTP
Project description:In this study gene expression profiles for 307 cases of advanced bladder cancers were compared to molecular phenotype at the tumor cell level. TUR-B tissue for RNA extraction was macrodissected from the close vicinity of the tissue sampled for immunohistochemistry to ensure high-quality sampling and to minimize the effects of intra-tumor heterogeneity. Despite excellent agreement between gene expression values and IHC-score at the single marker level, broad differences emerge when samples are clustered at the global mRNA versus tumor cell (IHC) levels. Classification at the different levels give different results in a systematic fashion, which implicates that analysis at both levels is required for optimal subtype-classification of bladder cancer.